Escitalopram oxalate
Based on 11 publication(s) in Google Scholar
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.97%
- CAS No.: 219861-08-2
- Formule: C22H23FN2O5
- Masse moléculaire:414.43
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Food-Sourced Compound Library
HY-L094
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Escitalopram oxalate
More- Phytomedicine. 2023 Dec:121:155083. [Abstract]
- Brain Behav Immun. 2026 Jan 26:134:106471. [Abstract]
- Transl Psychiatry. 2025 Feb 17;15(1):54. [Abstract]
- Geroscience. 2026 Mar 5. [Abstract]
- Int Immunopharmacol. 2025 Jan 6:147:113969. [Abstract]
- Mol Neurobiol. 2022 May;59(5):2855-2873. [Abstract]
- Brain Sci. 2025 Feb 24;15(3):236. [Abstract]
- J Clin Psychopharmacol. 2021 Sep-Oct;41(5):525-533. [Abstract]
- PLoS One. 2025 Aug 18;20(8):e0326134. [Abstract]
- Brain Mechanisms. 2025 Nov 21.
- SSRN. 2024 Oct 14.
Activité biologique
Ki: 0.89 nM (serotonin transporter), 10500 nM (DAT), 8150 nM (NET)[1]
Chronic administration of Escitalopram (daily; drinking water for a total of 4 months) significantly reduces plaque load by 28% and 34% at 2.5 and 5 mg/d, respectively [4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats[3]
-
Dosage:10 mg/kg
-
Administration:I.p.; daily for 28 days
-
Result:Could selectively decrease phosphorylated tau accumulation in the hippocampus of stressed rats and could distinctly alleviate the hyperactivity of the HPA axis in both depressive and resistant rats.
-
Animal Model:APP-PS1 hemizygous female mice (4 months of age)[4]
-
Dosage:2.5-5 mg/kg
-
Administration:Daily; drinking water for a total of 4 months
-
Result:At both doses significantly reduced plaque burden within the brains of these mice compared to littermate controls that drank only water. Hippocampal plaque load was significantly reduced by 28.7% and 34.4 % for ESC 2.5 mg/day and 5 mg/day, respectively.
Chemical Information
-
CAS No. 219861-08-2
-
Appearance Solid
-
Masse moléculaire 414.43
-
Formule C22H23FN2O5
-
Color White to off-white
-
SMILES
FC1=CC=C([C@@]2(CCCN(C)C)C(C=CC(C#N)=C3)=C3CO2)C=C1.O=C(O)C(O)=O
-
Synonyms
(S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Ginsenoside Rb1 protects hippocampal neurons in depressed rats based on mitophagy-regulated astrocytic pyroptosis. [Abstract]2023 Dec:121:155083. PMID: 37722244 -
Brain Behav Immun
Depression-related chronic stress promotes ovarian cancer progression via metabolic dysfunction and IRF1-mediated immune suppression. [Abstract]2026 Jan 26:134:106471. PMID: 41605304 -
Transl Psychiatry
Association of escitalopram-induced shifts in gut microbiota and sphingolipid metabolism with depression-like behavior in wistar-kyoto rats. [Abstract]2025 Feb 17;15(1):54. PMID: 39962083 -
Geroscience
2026 Mar 5. PMID: 41781498 -
Int Immunopharmacol
Innovative role of the antidepressant imipramine in esophageal squamous cell carcinoma treatment: Promoting apoptosis and protective autophagy. [Abstract]2025 Jan 6:147:113969. PMID: 39764996 -
Mol Neurobiol
Ginsenoside Rg1 Reduced Microglial Activation and Mitochondrial Dysfunction to Alleviate Depression-Like Behaviour Via the GAS5/EZH2/SOCS3/NRF2 Axis. [Abstract]2022 May;59(5):2855-2873. PMID: 35230663 -
Brain Sci
The pCREB/BDNF Pathway in the Hippocampus Is Involved in the Therapeutic Effect of Selective 5-HT Reuptake Inhibitors in Adult Male Rats Exposed to Blast Traumatic Brain Injury. [Abstract]2025 Feb 24;15(3):236. PMID: 40149758 -
J Clin Psychopharmacol
Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. [Abstract]2021 Sep-Oct;41(5):525-533. PMID: 34121064 -
PLoS One
Untargeted metabolomics reveals quinic acid as the kiwifruit component that affects brain activity in mice. [Abstract]2025 Aug 18;20(8):e0326134. PMID: 40824948 -
-
Solvant et solubilité
DMSO : 116.67 mg/mL (281.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 14.29 mg/mL (34.48 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: ≥ 100 mg/mL (241.30 mM); Clear solution
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (458 KB)
- English - EN (458 KB)
- Français - FR (458 KB)
- Deutsch - DE (458 KB)
- Norwegian - NO (458 KB)
- Español - ES (458 KB)
- Swedish - SV (458 KB)
- Italian - IT (458 KB)
- Portuguese - PT (458 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53(16): p. 6112-21. [Content Brief]
[2]. Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10(1): p. 121-8. [Content Brief]
[3]. Wu C , et al. Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity. Neurobiol Aging. 2018;67:137-147. [Content Brief]
[4]. Cirrito JR, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95(19):e2666-e2674. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.4130 mL | 12.0648 mL | 24.1295 mL | 60.3238 mL |
| 5 mM | 0.4826 mL | 2.4130 mL | 4.8259 mL | 12.0648 mL | |
| 10 mM | 0.2413 mL | 1.2065 mL | 2.4130 mL | 6.0324 mL | |
| 15 mM | 0.1609 mL | 0.8043 mL | 1.6086 mL | 4.0216 mL | |
| 20 mM | 0.1206 mL | 0.6032 mL | 1.2065 mL | 3.0162 mL | |
| 25 mM | 0.0965 mL | 0.4826 mL | 0.9652 mL | 2.4130 mL | |
| 30 mM | 0.0804 mL | 0.4022 mL | 0.8043 mL | 2.0108 mL | |
| DMSO | 40 mM | 0.0603 mL | 0.3016 mL | 0.6032 mL | 1.5081 mL |
| 50 mM | 0.0483 mL | 0.2413 mL | 0.4826 mL | 1.2065 mL | |
| 60 mM | 0.0402 mL | 0.2011 mL | 0.4022 mL | 1.0054 mL | |
| 80 mM | 0.0302 mL | 0.1508 mL | 0.3016 mL | 0.7540 mL | |
| 100 mM | 0.0241 mL | 0.1206 mL | 0.2413 mL | 0.6032 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz